推荐产品
产品名称
ALLN, Cell-permeable inhibitor of calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM).
质量水平
方案
≥95% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
颜色
white to off-white
溶解性
DMSO: 10 mg/mL
ethanol: 5 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
N([C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C=O)C(=O)[C@@H](NC(=O)C)CC(C)C
InChI
1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1
InChI key
FMYKJLXRRQTBOR-BZSNNMDCSA-N
一般描述
钙蛋白酶I（Ki=190 nM），钙蛋白酶II（Ki=220 nM），组织蛋白酶B（Ki=150 nM）和组织蛋白酶L（Ki=500 pM）的抑制剂。抑制中性半胱氨酸蛋白酶和蛋白酶体（Ki = 6 µM）。防止缺氧和缺血引起的神经元损伤。抑制胸腺细胞和晚幼粒细胞中的凋亡。通过抑制细胞周期蛋白B降解，抑制CHO细胞中G1/S边界和中期/后期的细胞周期进程。还可以通过干扰诱导型一氧化氮合酶基因的转录来防止活化巨噬细胞产生一氧化氮。抑制泛素-蛋白酶体复合物对IκBα和IκBβ的蛋白水解作用。
钙蛋白酶I（Ki=190 nM），钙蛋白酶II（Ki=220 nM），组织蛋白酶B（Ki=150 nM）和组织蛋白酶L（Ki=500 pM）的细胞可渗透抑制剂。抑制中性半胱氨酸蛋白酶和蛋白酶体（Ki = 6 µM）。调节β-淀粉样前体蛋白（βAPP）至β-淀粉样蛋白（Aβ）的加工。防止缺氧和缺血引起的神经元损伤。抑制胸腺细胞和晚幼粒细胞中的凋亡。还抑制L929细胞中呼肠孤病毒诱导的凋亡。抑制泛素-蛋白酶体复合物对IκBα和IκBβ的蛋白水解作用。通过抑制细胞周期蛋白B降解，抑制CHO细胞G1/S和中期/后期的细胞周期进程。还可以通过干扰诱导型一氧化氮合酶基因的转录来防止活化巨噬细胞产生一氧化氮。也可购买10 mM（5 mg/1.30 ml）ALLN的DMSO溶液（目录号208750）。
生化/生理作用
针对钙蛋白酶I、钙蛋白酶II、组织蛋白酶B和组织蛋白酶L分别为190 nM、220 nM、150 nM、500 pM
主要靶标
钙蛋白酶I
钙蛋白酶I
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
警告
毒性：标准处理（A）
序列
N-Acetyl-Leu-Leu-Nle-CHO
重悬
复溶后，等分并冷冻保存（-20°C）。储备液在-20°C条件下可稳定保存6个月。
其他说明
Debiasi, R.L., et al. 1999.J. Virol.73, 695.
Zhang, L., et al. 1999.J. Biol. Chem.274, 8966.
Milligan, S.A., et al. 1996.Arch.Biochem.Biophys.335, 388.
Griscavage, J.M., et al. 1995.Biochem.Biophys.Res. Commun.215, 721.
Squier, M.K., et al. 1994.J. Cell Physiol.159, 229.
Rami, J., and Kreiglstein, J. 1993.Brain Res.609, 67.
Sherwood, S.W., et al. 1993.Proc.Natl.Acad.Sci.USA90, 3353.
Vinitsky, A., et al. 1992.Biochemistry31, 9421.
Sasaki, T., et al. 1990.J. Enzyme Inhib.3, 195.
Zhang, L., et al. 1999.J. Biol. Chem.274, 8966.
Milligan, S.A., et al. 1996.Arch.Biochem.Biophys.335, 388.
Griscavage, J.M., et al. 1995.Biochem.Biophys.Res. Commun.215, 721.
Squier, M.K., et al. 1994.J. Cell Physiol.159, 229.
Rami, J., and Kreiglstein, J. 1993.Brain Res.609, 67.
Sherwood, S.W., et al. 1993.Proc.Natl.Acad.Sci.USA90, 3353.
Vinitsky, A., et al. 1992.Biochemistry31, 9421.
Sasaki, T., et al. 1990.J. Enzyme Inhib.3, 195.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Jin-Kai Wang et al.
Circulation, 145(9), 675-687 (2022-02-23)
High blood cholesterol accelerates the progression of atherosclerosis, which is an asymptomatic process lasting for decades. Rupture of atherosclerotic plaques induces thrombosis, which results in myocardial infarction or stroke. Lowering cholesterol levels is beneficial for preventing atherosclerotic cardiovascular disease. Low-density
J Michael Younger et al.
Methods in molecular biology (Clifton, N.J.), 301, 293-303 (2005-05-27)
Components of the ubiquitin-proteasome system function on the surface of the endoplasmic reticulum (ER) to select misfolded proteins for degradation. Herein we describe methods that allow for the study of the pathway for proteasomal degradation of the cystic fibrosis transmembrane
Abdallah Mound et al.
PloS one, 18(1), e0279028-e0279028 (2023-01-21)
Nod-Like Receptor Pyrin domain-containing protein 6 (NLRP6), a member of the Nucleotide-oligomerization domain-Like Receptor (NLR) family of proteins, assembles together with the ASC protein to form an inflammasome upon stimulation by bacterial lipoteichoic acid and double-stranded DNA. Besides its expression
Shiqian Han et al.
iScience, 26(5), 106613-106613 (2023-05-02)
Niemann-Pick disease type C (NP-C) is a genetic lysosomal disorder associated with progressive neurodegenerative phenotypes. Its therapeutic options are very limited. Here, we show that lithium treatment improves ataxia and feeding phenotypes, attenuates cerebellar inflammation and degeneration, and extends survival
Yi-Hsin Liang et al.
Journal of biomedical science, 28(1), 75-75 (2021-11-12)
A new strategy, particularly a novel combination, for immunotherapy in microsatellite stable metastatic colorectal cancer (mCRC) treatment needs to be formulated. Studies on the interferon-γ (IFN-γ)/ Janus kinase (JAK)/ signal transducer and activator of transcription (STAT)1 pathway provide new directions
相关内容
Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门